Alexion Pharma Lifts FY17 Adj. EPS, Revenue View - Quick Facts

(RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) on Thursday said it has lowered its earnings per share guidance for fiscal 2017, increased adjusted earnings per share view and increased the low-end of its revenue guidance. For the year, the company now expects reported earnings per share of $2.00 to $2.35, down from previously expected $2.82 to $3.12.

Adjusted earnings per share are now expected to be $5.50 to $5.65, compared to previous view of $5.40 to $5.55.

Total revenues are now expected to be $3.48 billion to $3.53 billion, compared to previous estimate of $3.45 billion to $3.53 billion.

On average, 20 analysts polled by Thomson Reuters expect earnings of $5.6 per share on revenues of $3.52 billion for the year. Analysts' estimates typically exclude special items.

Ludwig Hantson, Chief Executive Officer of Alexion said, "We also announced a restructuring that aligns the global organization with our strategy and we expect to deliver significant savings. We enter the fourth quarter of 2017 in a position of strength and are confident in our strategic plan to build long-term sustainable value for shareholders."